Literature DB >> 104946

CC-1065 (NSC-298223), a new antitumor antibiotic. Production, in vitro biological activity, microbiological assays and taxonomy of the producing microorganism.

L J Hanka, A Dietz, S A Gerpheide, S L Kuentzel, D G Martin.   

Abstract

A new antitumor antibiotic is produced in fermentation liquors of Streptomyces zelensis sp.n. The antibiotic is biologically active at extremely low concentrations. At 40 pg/ml, it inhibited 90% of the growth of L1210 cells in culture in tube dilution assays. The minimal inhibitory concentrations against Gram-positive bacteria is between 1 approximately 10 ng/ml, while these values for Gram-negative bacteria and fungi are mostly under 1 microgram/ml. A microbiological assay with Bacillus subtilis can detect concentrations of 1 approximately 2 ng/ml.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 104946     DOI: 10.7164/antibiotics.31.1211

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  21 in total

1.  Spectrum of cell-cycle kinetics of alkylating agent adolezesin in gynecological cancer cell lines: correlation with drug-induced cytotoxicity.

Authors:  H N Nguyen; B U Sevin; H Averette; J Perras; R Ramos; D Donato
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

2.  In vitro evaluation of a novel chemotherapeutic agent, Adozelesin, in gynecologic-cancer cell lines.

Authors:  H N Nguyen; B U Sevin; H Averette; J Perras; R Hightower; R Ramos; D Donato; M Penalver
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

3.  Facile formation of a crosslinked adduct between DNA and the daunorubicin derivative MAR70 mediated by formaldehyde: molecular structure of the MAR70-d(CGTnACG) covalent adduct.

Authors:  Y G Gao; Y C Liaw; Y K Li; G A van der Marel; J H van Boom; A H Wang
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-01       Impact factor: 11.205

4.  Theoretical study of the sequence specificity in the covalent binding of the antitumor drug CC-1065 to DNA.

Authors:  K Zakrzewska; M Randrianarivelo; B Pullman
Journal:  Nucleic Acids Res       Date:  1987-07-24       Impact factor: 16.971

5.  Demonstration of the asymmetric effect of CC-1065 on local DNA structure using a site-directed adduct in a 117-base-pair fragment from M13mp1.

Authors:  L H Hurley; D R Needham-VanDevanter; C S Lee
Journal:  Proc Natl Acad Sci U S A       Date:  1987-09       Impact factor: 11.205

6.  Mode of action of C-1027, a new macromolecular antitumor antibiotic with highly potent cytotoxicity, on human hepatoma BEL-7402 cells.

Authors:  Y J Xu; D D Li; Y S Zhen
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

7.  Preclinical pharmacology of bizelesin, a potent bifunctional analog of the DNA-binding antibiotic CC-1065.

Authors:  D L Walker; J M Reid; M M Ames
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

8.  Phase I trial of Adozelesin using the treatment schedule of daily x5 every 3 weeks.

Authors:  B J Foster; P M LoRusso; E Poplin; M Zalupski; M Valdivieso; A Wozniak; L Flaherty; D A Kasunic; R H Earhart; L H Baker
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

9.  Adozelesin, a selected lead among cyclopropylpyrroloindole analogs of the DNA-binding antibiotic, CC-1065.

Authors:  L H Li; R C Kelly; M A Warpehoski; J P McGovren; I Gebhard; T F DeKoning
Journal:  Invest New Drugs       Date:  1991-05       Impact factor: 3.850

10.  Structure and activity relationship of several novel CC-1065 analogs.

Authors:  L H Li; T L Wallace; T F DeKoning; M A Warpehoski; R C Kelly; M D Prairie; W C Krueger
Journal:  Invest New Drugs       Date:  1987-12       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.